Ozempic vs Mounjaro: Which GLP-1 Produces More Weight Loss?
Medically reviewed by Medical Advisory Board Last reviewed 2026-06-15
Semaglutide vs tirzepatide — different mechanisms, different results
Ozempic (semaglutide) and Mounjaro (tirzepatide) are both weekly GLP-1 injections, but Mounjaro also targets the GIP receptor — and that second mechanism produces meaningfully more weight loss in head-to-head trials. This guide compares mechanism, weight-loss results, side effects, cost, and who each drug suits.
Ozempic vs Mounjaro is the most-asked GLP-1 question right now, and for good reason: they look similar on the surface — both are weekly injections for Type 2 diabetes — but they are not the same drug and do not produce the same results. Ozempic is semaglutide, a pure GLP-1 receptor agonist. Mounjaro is tirzepatide, a dual GIP/GLP-1 receptor agonist that works two pathways simultaneously.
For context on the whole GLP-1 drug class, start with our GLP-1 peptides guide. For what happens when weight loss stalls on either drug, see our GLP-1 plateau guide.
Ozempic vs Mounjaro: Head-to-Head
| Factor | Ozempic (semaglutide) | Mounjaro (tirzepatide) |
|---|---|---|
| Drug class | GLP-1 receptor agonist | GIP + GLP-1 dual receptor agonist |
| FDA approval | Type 2 diabetes (Ozempic); obesity (Wegovy) | Type 2 diabetes (Mounjaro); obesity (Zepbound) |
| Dosing | 0.5–2 mg weekly injection | 2.5–15 mg weekly injection |
| Average weight loss (trials) | ~12–15% body weight (SUSTAIN/STEP trials) | ~15–22% body weight (SURPASS/SURMOUNT trials) |
| A1C reduction | Strong (SUSTAIN series) | Stronger at higher doses (SURPASS series) |
| GI side effects | Nausea, vomiting, diarrhea during titration | Similar; possibly higher nausea rates at initiation |
| CV outcomes data | Yes (SUSTAIN-6, SELECT trial) | Emerging (SURPASS-CVOT pending full publication) |
| Cost (without coverage) | ~$900–$1,000/month | ~$1,000–$1,100/month |
Why Mounjaro Produces More Weight Loss
Semaglutide acts on GLP-1 receptors, slowing gastric emptying and reducing appetite through brain signaling. Tirzepatide does all of that but also activates GIP receptors — and GIP appears to amplify GLP-1's appetite-suppressing effect and improve the metabolic handling of fat. The result in the SURMOUNT-1 trial was average weight loss of 20.9% at 72 weeks on 15 mg tirzepatide versus 14.9% for semaglutide 2.4 mg (Wegovy) in the STEP-1 trial, though the trials weren't directly head-to-head.
A 2024 real-world study (JAMA) comparing the two drugs directly did show statistically significant greater weight loss with tirzepatide at one year.
When Ozempic Is the Better Choice
Ozempic may suit you better if:
- You or your insurer are more comfortable with its longer safety and outcomes track record (it has been available since 2017).
- You have established cardiovascular disease — SELECT trial data directly supports semaglutide for CV risk reduction.
- Supply or access favors semaglutide in your area.
- You have previously tolerated semaglutide and are dose-stable.
When Mounjaro Is the Better Choice
Mounjaro may suit you better if:
- Maximizing weight loss is the primary goal and you are willing to titrate to 10–15 mg.
- Blood sugar control at high A1C needs stronger pharmacological support.
- You have not responded well enough to semaglutide.
If you are choosing between the weight-loss-approved brands, see our Wegovy vs Zepbound guide for the obesity-indication framing.
The Verdict
For weight loss, tirzepatide (Mounjaro/Zepbound) has better trial numbers. For CV outcomes evidence and longer-term safety data, semaglutide (Ozempic/Wegovy) has the edge. Both are excellent drugs. If weight loss is your primary goal and you have no contraindications, the evidence currently favors tirzepatide. If cardiovascular protection matters most, semaglutide has the stronger outcomes data. A clinician who knows your full history is the right person to make the call — start with our free metabolic assessment or book a consultation.
Frequently Asked Questions
Is Mounjaro stronger than Ozempic?
In terms of average weight loss in clinical trials, yes — tirzepatide (Mounjaro/Zepbound) produces more weight loss on average than semaglutide (Ozempic/Wegovy). The SURMOUNT-1 trial showed ~20.9% body weight loss at the highest tirzepatide dose versus ~14.9% in the semaglutide STEP-1 trial, though these were separate studies. A 2024 real-world head-to-head study confirmed meaningfully greater weight loss with tirzepatide at one year.
Can you switch from Ozempic to Mounjaro?
Yes, switching is done under medical supervision. Because both drugs affect GLP-1 receptors, the transition typically involves stopping semaglutide and starting tirzepatide at a low dose with titration. Some people switch when Ozempic stops producing results; others switch for insurance or supply reasons. Your clinician will guide the timing and starting dose.
Are Ozempic and Mounjaro covered by insurance?
Coverage varies significantly by insurer and indication. Both are FDA-approved for Type 2 diabetes, which has broader coverage. The obesity-branded versions (Wegovy and Zepbound) face more variable insurance hurdles. Many commercial plans have added GLP-1 coverage in 2024–2025, but Medicare Part D coverage for weight loss specifically was limited until the Treat and Reduce Obesity Act provisions. Always verify your plan's prior authorization requirements before starting.
What are the side effects of Ozempic vs Mounjaro?
Both cause similar GI side effects — nausea, vomiting, diarrhea, and constipation — most prominently during dose escalation. These typically improve over the first 4–8 weeks. Both carry a black-box warning about thyroid C-cell tumors based on rodent data (clinical significance unclear). Pancreatitis is a rare risk with both. Mounjaro may have slightly higher early nausea rates due to the GIP component. Neither should be used in pregnancy.
Topic updates
Get the weekly metabolic health roundup
Insulin resistance, blood sugar, visceral fat, GLP-1 plateaus, metabolic syndrome, and weight-loss physiology.
Check Where You Stand
Take our free health assessment to understand your metabolic, hormonal, and recovery risk factors — and get personalized recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results
Continue Reading
-
What is insulin resistance? Causes, symptoms & how to reverse it
What insulin resistance is, how to test for it, and how to reverse it.
-
Metabolic syndrome — diagnosis, risks, and treatment
The five diagnostic criteria and what they mean for your health.
-
Insulin resistance symptoms: 12 warning signs
12 clinical warning signs, from acanthosis nigricans to post-meal fatigue.
-
Blood sugar crash: why it happens and how to stop it
Reactive hypoglycemia: causes, symptoms, and how to stabilize glucose.
-
Glucose spikes after eating: causes and what to do
Why blood sugar spikes after eating and what to do about it.
-
Fatigue after eating: why food makes you tired
Post-meal fatigue explained — insulin, glucose, and the gut-brain axis.
-
Hypoglycemia symptoms: low blood sugar warning signs
Low blood sugar warning signs and when to seek medical attention.
-
How to reverse insulin resistance naturally
Evidence-based dietary and lifestyle interventions (3-16 week timeline).
-
Slow metabolism: myths, causes, and what actually works
Why metabolism slows, what's myth vs reality, and what the evidence says.
-
Visceral fat: why it's dangerous and how to lose it
Visceral vs subcutaneous fat — why waist circumference matters more than BMI.